Hospitalization for Lower Respiratory Tract Disease in Preterm Infants: Effects of Prophylaxis with Palivizumab

Journal of Chemotherapy

Volumn 22, Issue 1, 2010, Pages 30-35

  Faldella, Giacomo ^a   Alessandroni, R ^a   Aquilano, G ^a   Vandini, S ^b   Lanari, M ^b   Silvestri, M ^c   Pistorio, A ^c   Rossi, G A ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Hospital of Imola   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Admitting department; Hospital; Palivizumab; Preterm birth; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEWBORN INTENSIVE CARE; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TREATMENT RESPONSE;

EID: 77950169060     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.1.30     Document Type: Article

References (34)

1. Bosis S, Esposito S, Niesters HG, Zoccotti GV, Marseglia G, Lanari M, et al. Role of respiratory pathogens in infants hospitalized for a first episode of wheezing and their impact on recurrences. Clin Microbiol Infect 2008; 14(7): 677-684.
2. Corsello G, Di Carlo P, Salsa L, Gabriele B. Meli L, Bruno S, Titone L. Respiratory syncytial virus infection in a Sicilian pediatric population: risk factors, epidemiology, and severity. Allergy Asthma Proc 2008; 29(2): 205-210.
3. Fabbiani M, Terrosi C, Martorelli B, Valentini M, Bernini L, Cellesi C, Cusi MG. Epidemiological and clinical study of viral respiratory tract infections in children from Italy. J Med Virol 2009; 81(4): 750-756.
4. Welliver R. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003; 143 (Suppl.5): S112-S117.
5. Carbonell-Estrany X, Figueras-Aloy J, Law B. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004; 23 (Suppl 11): S193-S201.
6. Rossi G, Modici M, Arcangeletti M, Lanari M, Morolla R, Paparatti UD et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007; 166 (12): 1267-1272.
7. Smyth R, Opanshaw P. Bronchiolitis. Lancet 2006; 368 (9532): 312-322.
8. Meissner H, Welliver R, Chartrand S, Law B, Weisman L, Dorkin HL, et al. Immunoprophylaxis with palivizomab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncyhial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999; 18 (3): 223-231.
9. No authors listed. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3 Pt 1): 53 1-537.
10. American Academy of Pediatrics. AAP guidelines for RSV immunoprophylaxis. Redbook 2009.
11. Parnes C, Guillermen J, Habarsang R, Nicholes P, Chawla V, Kelly T et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001; results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003; 35 (6): 484-489.
12. Klimek M, Kwinta P, Kruczek P, Pietrzyk JJ. Respiratory syncytial virus prophylaxis among preterm infants-four seasons' experience. Przegl Lek 2009; 66 (1-2): 34-38.
13. Puddu M, Fanos V. Respiratory syncytial virus infection and recurrent wheezing: what next? J Chemother 2007; 19 (Suppl 2): 8-11.
14. Corsello G. Bronchiolitis: the new American Academy of Pediatrics guidelines. J Chemother 2O07 19 (Suppl 2): 12-14.
15. American Academy of Pediatrics Committee no Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102 (2): 1211-1216.
16. Canadian Paediatric Society (CPS) IDaIC. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Heath 1999; 4 (7): 474-480.
17. Forster J. Prophylaxis of RSV infections with immunoglobulins. Report of the German Society of Pediatric Infectiology (DGPI). Monalsschrift Kinderheilkunde, 1999; 10: 971-972.
18. Azar P, Broglia B. Miceli I, Parga L, Castillo E, et al. Guidelines for the use of palivizumab in the prevention of RSV disease: a consensus opinion. Pediatr Rae (Spanish), 2000; 21: 62-68.
19. Marini A. Raccomandazioni per la prevenzione della malattia do virus respiratorio sinciziale (RSV). Riv Ital Pediatr, 2000; 26: 379-381.
20. Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol. 2006; 41. (12): 1167-1174.
21. Wang E, Law B, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lowar respiratory tract infection. J Pediatr. 1995; 126 (2): 212-219.
22. Joffe S, Escobar C, Black S, Armstrong M, Lieu T. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999; 104(4 Pt 1): 894-899.
23. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Gruop. Pediatr Infect Dis J 2000; 19 (7): 592-597.
24. Hack M, DeMonterice D, Merkatz I, Jones P, Fanaroff A. Rehospitalization of the very-low-birth-weight infant. A continuum of perinatal and environmental morbidity. Am J Dis Child. 1981; 135 (3): 263-266.
25. McCormick M, Shapiro S, Starfield B. Rehospitalization in the first year of life for high-risk survivors. Pediatrics 1980; 66 (6): 991-999.
26. Imogen Morgan M. Late morbidity of very low birthwaight infants. Br Med J Clin Rev Ed) 1985; 291 (6489): 171-173.
27. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997; 99 (1): 93-99.
28. Sauve R, Singhal N. Long-term morbidity of infants with bronchopulmunary dysplasia. Pediatrics. 1985; 76 (5): 725-733.
29. Stevens T, Sinkin R, Hall C, Maniscalco W, McConnochie K. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Padiatr Adolesc Med. 2000; 154 (1): 55-61.
30. Kusuda S, Koizumi; T, Sakai T, Fujimura M, Nishida H, Togari H. Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. Padiatr Int. 2006, 48 (4): 362-368.
31. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Padiatr Infect Dis J. 2003; 22 (9): 823-827.
32. Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmanary dysplasia. Pediatr Pulmonol. 2007; 42 (7): 189-192.
33. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28(7): 511-517.
34. Fanos V, Scarcella A, Poddu M, Gallini F, Tuminelli F, Bragetti P, at al. Respiratory disorder and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season. J Chemother 2009; 21 (3): 302-310.